| Name | Title | Contact Details |
|---|
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.
BNP Paribas is a leading bank in Europe with an international reach. It has a presence in 65 countries, with more than 190,000 employees, including more than 145,000 in Europe. BNP Paribas holds leading positions in its three major operating divisions: ⚆ Commercial, Personal Banking & Services for all the Groups retail banking networks and several specialised businesses, including BNP Paribas Personal Finance and Arval; ⚆ Investment & Protection Services for savings, investment and protection solutions; ⚆ Corporate & Institutional Banking, which is focused on corporate and institutional clients. The Group helps all its clients (individuals, community associations, entrepreneurs, SMEs, corporates and institutional clients) to realise their projects through solutions spanning financing, investment, savings and protection insurance. In Europe, the Group has four domestic markets (Belgium, France, Italy and Luxembourg) and BNP Paribas Personal Finance is the European leader in consumer lending. BNP Paribas is rolling out its integrated retail-banking model in Mediterranean countries, in Turkey, in Eastern Europe and a large network in the western part of the United States. In its Corporate & Institutional Banking and Investment & Protection Services activities, BNP Paribas also enjoys top positions in Europe, a strong presence in the Americas as well as a solid and fast-growing business in Asia-Pacific. To learn more about our social media terms and Data Protection Notice: https://group.bnpparibas/en/data-protection
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.